1. A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia Schimmer, Aaron D.; Raza, Azra; Carter, Thomas H.; Claxton, David; Erba, Harry; DeAngelo, Daniel J.; Tallman, Martin S.; Goard, Carolyn; Borthakur, Gautam 2014 Articles Cancer--TreatmentAcute myeloid leukemiaNeutrophilsOncologyMedicine
2. Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts Kode, Aruna; Manavalan, John S.; Mosialou, Ioanna; Bhagat, Govind; Rathinam, Chozha Vendan; Luo, Na; Khiabanian, Hossein; Lee, Albert Kim; Vundavalli, Murty V.; Friedman, Richard A.; Brum, Andrea; Park, David; Galili, Naomi; Mukherjee, Siddhartha; Teruya-Feldstein, Julie; Raza, Azra; Rabadan, Raul; Berman, Ellin; Kousteni, Stavroula 2014 Articles Leukemia--EtiologyOsteoblastsCateninsCarcinogenesisPathologyMedicine
3. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) Raza, Azra; Galili, Naomi; Mulford, Deborah; Smith, Scott; Brown, Gail; Steensma, David; Lyons, Roger; Boccia, Ralph; Sekeres, Mikkael; Garcia-Manero, Guillermo; Mesa, Ruben 2012 Articles MedicineOncology
4. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome Galili, Naomi; Tamayo, Pablo; Botvinnik, Olga; Mesirov, Jill; Brooks, Margarita; Brown, Gail; Raza, Azra 2012 Articles MedicineOncology